Patents by Inventor Mark J. Evans
Mark J. Evans has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200392216Abstract: Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglohinuria (PNH). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global Phase III trial. It has been found that eculizumab stabilized hemoglobin levels, decreased the need for transfusions, and improved quality of life in PNH patients via reduced intravascular hemolysis. Chronic eculizumab treatment appears to be a safe and effective therapy for PNH.Type: ApplicationFiled: January 23, 2020Publication date: December 17, 2020Inventors: Leonard BELL, Russell P. ROTHER, Mark J. EVANS
-
Patent number: 10703809Abstract: Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global Phase III trial. It has been found that eculizumab stabilized hemoglobin levels, decreased the need for transfusions, and improved quality of life in PNH patients via reduced intravascular hemolysis. Chronic eculizumab treatment appears to be a safe and effective therapy for PNH.Type: GrantFiled: February 28, 2020Date of Patent: July 7, 2020Assignee: Alexion Pharmaceuticals, Inc.Inventors: Leonard Bell, Russell P. Rother, Mark J. Evans
-
Publication number: 20200199211Abstract: Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global Phase III trial. It has been found that eculizumab stabilized hemoglobin levels, decreased the need for transfusions, and improved quality of life in PNH patients via reduced intravascular hemolysis. Chronic eculizumab treatment appears to be a safe and effective therapy for PNH.Type: ApplicationFiled: February 28, 2020Publication date: June 25, 2020Inventors: Leonard BELL, Russell P. ROTHER, Mark J. EVANS
-
Patent number: 10590189Abstract: Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global Phase III trial. It has been found that eculizumab stabilized hemoglobin levels, decreased the need for transfusions, and improved quality of life in PNH patients via reduced intravascular hemolysis. Chronic eculizumab treatment appears to be a safe and effective therapy for PNH.Type: GrantFiled: July 5, 2017Date of Patent: March 17, 2020Assignee: Alexion Pharmaceuticals, Inc.Inventors: Leonard Bell, Russell P. Rother, Mark J. Evans
-
Publication number: 20170349652Abstract: Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global Phase III trial. It has been found that eculizumab stabilized hemoglobin levels, decreased the need for transfusions, and improved quality of life in PNH patients via reduced intravascular hemolysis. Chronic eculizumab treatment appears to be a safe and effective therapy for PNH.Type: ApplicationFiled: July 5, 2017Publication date: December 7, 2017Inventors: Leonard BELL, Russell P. ROTHER, Mark J. EVANS
-
Patent number: 9732149Abstract: Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global Phase III trial. It has been found that eculizumab stabilized hemoglobin levels, decreased the need for transfusions, and improved quality of life in PNH patients via reduced intravascular hemolysis. Chronic eculizumab treatment appears to be a safe and effective therapy for PNH.Type: GrantFiled: October 3, 2016Date of Patent: August 15, 2017Assignee: Alexion Pharmaceuticals, Inc.Inventors: Leonard Bell, Russell P. Rother, Mark J. Evans
-
Patent number: 9725504Abstract: Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global Phase III trial. It has been found that eculizumab stabilized hemoglobin levels, decreased the need for transfusions, and improved quality of life in PNH patients via reduced intravascular hemolysis. Chronic eculizumab treatment appears to be a safe and effective therapy for PNH.Type: GrantFiled: September 9, 2016Date of Patent: August 8, 2017Assignee: Alexion Pharmaceuticals, Inc.Inventors: Leonard Bell, Russell P. Rother, Mark J. Evans
-
Patent number: 9718880Abstract: Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global Phase III trial. It has been found that eculizumab stabilized hemoglobin levels, decreased the need for transfusions, and improved quality of life in PNH patients via reduced intravascular hemolysis. Chronic eculizumab treatment appears to be a safe and effective therapy for PNH.Type: GrantFiled: May 6, 2016Date of Patent: August 1, 2017Assignee: Alexion Pharmaceuticals, Inc.Inventors: Leonard Bell, Russell P. Rother, Mark J. Evans
-
Patent number: 8087063Abstract: A method for digitally preserving an electronic record includes defining a preservation and service plan for the electronic record in a model, the preservation and service plan including access requirements and authenticity requirements for a digital adaptation of the electronic record, and characteristics of the electronic record to be preserved in the digital adaptation of the electronic record, the model assigning a numeric value to each requirement and characteristic and to the relative importance of each requirement and characteristic; for each data type included in the electronic record, assigning a capability score to each digital adaptation processor that supports the data type, the capability score being indicative of the ability of the digital adaptation processor to meet the access and authenticity requirements and preserve the characteristics as valued in the model; and comparing the capability scores to determine the digital adaptation processor that most closely matches the model.Type: GrantFiled: May 4, 2007Date of Patent: December 27, 2011Assignees: Lockheed Martin Corporation, Fenestra Technologies Corporation, Tessella Inc.Inventors: Sean Martin, Roy S. Rogers, IV, Matthew J. McKennirey, Mark J. Evans
-
Patent number: 7792791Abstract: Systems and/or methods for establishing and maintaining authenticity of a plurality of records and/or documentary materials to be persisted in an electronic archives system are provided. Each record and/or documentary material may be safeguarded throughout its entire lifecycle by monitoring and recording both intended changes to each said record and/or documentary material and its corresponding status, as well as unintended changes to each said record and/or documentary material. Context and structure associated with each said record and/or documentary material may be extracted and preserved. Substantially uninterrupted proof-of-custody including at least a source may be established and preserved for each said record and/or documentary material throughout its entire lifecycle. Essential characteristics of each said record and/or documentary material may be captured and preserved throughout its lifecycle in dependence on one or more changeable definitions of essential characteristic.Type: GrantFiled: May 2, 2007Date of Patent: September 7, 2010Assignees: Lockheed Martin Corporation, Hunter Information Management Services, Inc., Fenestra Technologies Corporation, Tessella Inc., Electronic Data Systems CorporationInventors: Richard Smolen, Fred Y. Robinson, Gregory S. Hunter, Roy S. Rogers, IV, Matthew J. McKennirey, Mark J. Evans, Ken Bedford
-
Publication number: 20090163474Abstract: Provided are certain methods of treating nonalcoholic fatty liver disease with farnesoid X receptor agonists. Also provided are certain methods of modulating levels of keratinocyte-derived chemokine (KC), alanine aminotransferase (ALT), aspartate aminotransferase (AST), cytokeratin 18 (CK-18), matrix metalloproteinase-9 (MMP-9), matrix metalloproteinase-14 (MMP-14), tissue inhibitor of metalloproteinase 1 (TIMP-1), and Cytochrome P450 2E1 (CYP2E1); certain methods of identifying FXR modulators; and certain methods of treating patients with existing cholesterol gallstone disease.Type: ApplicationFiled: October 16, 2008Publication date: June 25, 2009Applicant: WyethInventors: Songwen Zhang, Douglas Harnish, Mark J. Evans, Juan Wang
-
Publication number: 20080299118Abstract: Provided are certain methods of treating maligancies with farnesoid X receptor agonists.Type: ApplicationFiled: May 30, 2008Publication date: December 4, 2008Applicant: WyethInventors: Helen B. Hartman, Mark J. Evans
-
Patent number: 7445920Abstract: The present invention relates to a novel lysyl oxidase genes, termed EER-7. The invention relates to the protein and nucleic acids encoding the protein. The invention further relates to an assay system to identify compounds that selectively modulate EER-7 protein activity by interaction with estrogen receptors.Type: GrantFiled: June 6, 2003Date of Patent: November 4, 2008Assignee: WyethInventors: Mark J. Evans, Marshall S. Scicchitano, Ashok R. Bapat, Ramesh A. Bhat, Robert Mastroeni, Sotirios K. Karathanasis
-
Publication number: 20070271258Abstract: A method for digitally preserving an electronic record includes defining a preservation and service plan for the electronic record in a model, the preservation and service plan including access requirements and authenticity requirements for a digital adaptation of the electronic record, and characteristics of the electronic record to be preserved in the digital adaptation of the electronic record, the model assigning a numeric value to each requirement and characteristic and to the relative importance of each requirement and characteristic; for each data type included in the electronic record, assigning a capability score to each digital adaptation processor that supports the data type, the capability score being indicative of the ability of the digital adaptation processor to meet the access and authenticity requirements and preserve the characteristics as valued in the model; and comparing the capability scores to determine the digital adaptation processor that most closely matches the model.Type: ApplicationFiled: May 4, 2007Publication date: November 22, 2007Applicants: LOCKHEED MARTIN CORPORATION, FENESTRA TECHNOLOGIES CORPORATION, TESSELLA INC.Inventors: Sean Martin, Roy S. Rogers, Matthew J. McKennirey, Mark J. Evans
-
Publication number: 20070260575Abstract: A method for managing electronic records is provided. Each electronic record includes a data file, a plurality of data files, a portion of a data file, or portions of a plurality of data files. The electronic records include a plurality of record types and data file types. The method includes forming a data file set comprising one or more logically related data files; identifying attributes of each record type in a record type template; identifying specifications of each data file type in a data file type template; and extracting digital components from the data file set. The extracted digital components relate to the attributes in each record type template and the specifications in each data file type template and compose an individual record. An electronic record archive includes record type and data file type templates and a digital component extractor.Type: ApplicationFiled: May 4, 2007Publication date: November 8, 2007Applicants: LOCKHEED MARTIN CORPORATION, FENESTRA TECHNOLOGIES CORPORATION, TESSELLA INC., HUNTER INFORMATION MANAGEMENT SERVICES, INC.Inventors: Fred Y. Robinson, Rodney J. Ripley, Roy S. Rogers, Matthew J. McKennirey, Mark J. Evans, Gregory S. Hunter
-
Patent number: 7208300Abstract: The present invention relates to a novel lysyl oxidase genes, termed EER-7. The invention relates to the protein and nucleic acids encoding the protein. The invention further relates to an assay system to identify compounds that selectively modulate EER-7 protein activity by interaction with estrogen receptors.Type: GrantFiled: August 8, 2001Date of Patent: April 24, 2007Assignee: WyethInventors: Mark J. Evans, Marshall S. Scicchitano, Ashok R. Bapat, Ramesh A. Bhat, Robert Mastroeni, Sotirios K. Karathanasis
-
Publication number: 20040171110Abstract: The present invention relates to a novel lysyl oxidase genes, termed EER-7. The invention relates to the protein and nucleic acids encoding the protein. The invention further relates to an assay system to identify compounds that selectively modulate EER-7 protein activity by interaction with estrogen receptors.Type: ApplicationFiled: June 6, 2003Publication date: September 2, 2004Applicant: WyethInventors: Mark J. Evans, Marshall S. Scicchitano, Ashok R. Bapat, Eric Beer, Ramesh A. Bhat, Elissa Ferris, Robert Mastroeni, Jianxiong Zhang, Sotirios K. Karathanasis
-
Publication number: 20020102645Abstract: The present invention relates to a novel lysyl oxidase genes, termed EER-7. The invention relates to the protein and nucleic acids encoding the protein. The invention further relates to an assay system to identify compounds that selectively modulate EER-7 protein activity by interaction with estrogen receptors.Type: ApplicationFiled: August 8, 2001Publication date: August 1, 2002Applicant: American Home Products CorporationInventors: Mark J. Evans, Marshall S. Scicchitano, Ashok R. Bapat, Eric Beer, Ramesh A. Bhat, Elissa Ferris, Robert Mastroeni, Jianxiong Zhang, Sotirios K. Karathanasis
-
Patent number: 6355245Abstract: The use of anti-C5 antibodies, e.g., monoclonal antibodies, to treat glomerulonephritis (GN) is disclosed. The administration of such antibodies at low dosage levels has been found to significantly reduce glomerular inflammation/enlargement and other pathologic conditions associated with GN. Also disclosed are anti-C5 antibodies and anti-C5 antibody-encoding nucleic acid molecules. These antibodies are useful in the treatment of GN and other inflammatory conditions involving pathologic activation of the complement system.Type: GrantFiled: June 7, 1995Date of Patent: March 12, 2002Assignee: Alexion Pharmaceuticals, Inc.Inventors: Mark J. Evans, Louis A. Matis, Eileen Elliott Mueller, Steven H. Nye, Scott Rollins, Russell P. Rother, Jeremy P. Springhorn, Stephen P. Squinto, Thomas C. Thomas, James A. Wilkins
-
Patent number: 6040428Abstract: A porcine E-selectin protein, its amino acid sequence, the sequence of a cDNA encoding the protein, antibodies reactive with the protein, and methods for the use of these molecules are disclosed. The molecules are used to diagnose the rejection of xenotransplanted pig organs, as well as to prevent and treat such transplant rejection.Type: GrantFiled: March 25, 1999Date of Patent: March 21, 2000Assignee: Alexion Pharmaceuticals, Inc.Inventors: Scott Rollins, Russell P. Rother, Louis A. Matis, Mark J. Evans